Molecular landscape observed in SM-t(8;21) AML and KITpos t(8;21) AML cases. (A-B) Alignment of top gene mutations in 23 patients with SM-t(8;21) AML and 147 patients with KITpos t(8;21) AML detected by targeted next-generation sequencing (over 50 genes). Each column represents 1 analyzed patient, and each line represents 1 gene. (C) Distribution of number of KIT gene mutations in patients with SM-t(8;21) AML and KITpos t(8;21) AML. (D) Pie charts showing the distribution of known KIT mutation subtypes in patients with SM-t(8;21) AML and those with KITpos t(8;21) AML for the most frequent codons and exons, with mutation frequencies shown as percentage. (E) Variant allele frequency (VAF) of KIT, KIT exon17, KIT D816, KITD816Y, and KIT N822K in SM-t(8;21) AML in comparison to KITpos t(8;21) AML. ns, not significant.

Molecular landscape observed in SM-t(8;21) AML and KITpos t(8;21) AML cases. (A-B) Alignment of top gene mutations in 23 patients with SM-t(8;21) AML and 147 patients with KITpos t(8;21) AML detected by targeted next-generation sequencing (over 50 genes). Each column represents 1 analyzed patient, and each line represents 1 gene. (C) Distribution of number of KIT gene mutations in patients with SM-t(8;21) AML and KITpos t(8;21) AML. (D) Pie charts showing the distribution of known KIT mutation subtypes in patients with SM-t(8;21) AML and those with KITpos t(8;21) AML for the most frequent codons and exons, with mutation frequencies shown as percentage. (E) Variant allele frequency (VAF) of KIT, KIT exon17, KIT D816, KITD816Y, and KIT N822K in SM-t(8;21) AML in comparison to KITpos t(8;21) AML. ns, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal